AbstergoAbstergo Industries, a multinational corporation, reported a successful year in genetic research in 2023, aiming for further developments in 2024. Specializing in the study and application of genetic data, Abstergo has made breakthroughs in areas like disease cure development and genetic traits identification. For 2024, they plan to enhance their genetic memory exploring device, the Animus, and expand their global data network, Eye-Abstergo.
Abstergo Industries is pioneering developments in cancer drug research, focusing on immunotherapy, targeted therapies, genetics of cancer, and prevention strategies. The company’s primary concern is their newly developed cancer drug, Oncolux, a targeted therapy displaying promising results in preclinical trials for its capacity to destroy cancer cells without harming healthy ones. Abstergo aims to revolutionize the field, aspiring to improve patient lives and contribute significantly to future cancer research.
Abstergo Industries is proud to announce our latest satellite program, the Akashic Satellite Plexus® 2.0. This program builds on the success of our previous satellite programs, including the original Akashic Satellite Plexus® launched in 2008 and the EYE-ABSTERGO® satellite launched in 2012. Our goal with this new program is to extend the reach and capabilities […]
Abstergo Industries is dedicated to advancing the science of aging and developing treatments to slow the aging process. Aging is a complex process that involves a variety of biological pathways and mechanisms, including genetic, environmental, and lifestyle factors. Our research focuses on understanding these pathways and developing interventions that can target them to extend healthy […]
Abstergo Industries is proud to announce the latest iteration of the Animus, the revolutionary device that allows our researchers to experience the genetic memories of our test subject’s ancestors. The Animus has been a key tool in our research into the field of genetic memory, and the new Animus represents a major step forward in […]
Abstergo